Tenafin - Butenafine Hydrochloride | VetSafeCare.Com

Crm.

Tenafin

Butenafine Hydrochloride — Beximco Pharmaceuticals Ltd.
1% / cream

Alternatives

3

Routes

TOP

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Cream · 1% / cream

15 gm

৳50

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

In the treatment of interdigital tinea pedis, Butenafine should be applied twice daily for 7 days or once daily for 4 weeks. Patients with tinea corporis or tinea cruris should apply Butenafine once daily for two weeks. Sufficient Butenafine cream should be applied to cover affected areas and immediately surrounding skin of patients with interdigital tinea pedis, tinea corporis and tinea cruris.

Clinical notes

Applications:

N/A

Indication Notes:
Butenafine cream is indicated for the topical treatment of the following superficial dermatophytosis: Interdigital tinea pedis (athlete's foot); Tinea corporis (ringworm); Tinea cruris (jock itch) due to E. floccosum, T. mentagrophytes, T. rubrum, and T. tonsurans.
Avoid In:

N/A

Contraindication Notes:
Butenafine Hydrochloride is contraindicated in individuals who have known or suspected sensitivity to this cream or any of its components.
Butenafine is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition. Butenafine is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well.
Potential drug interactions between butenafine HCl cream and other drugs have not been evaluated.
Rarely local mild burning or irritation may be experienced. Hypersensitivity reactions may occur.
Overdosage of butenafine HCl in humans has not been reported to date.
Pregnancy Category C. As no adequate and well-controlled studies have been conducted, this drug should be used during pregnancy only if clearly needed. It is not known if butenafine HCl is excreted in human milk. Caution should be exercised in prescribing butenafine HCl to a nursing woman.
Butenafine cream is not for ophthalmic, oral, or intravaginal use. This is for external use only. If irritation or sensitivity develops with the use of Butenafine cream, treatment should be discontinued and appropriate therapy instituted.
Safety and efficacy in pediatric patients below the age of 12 years have not been studied.